Bio Medica Laboratories Ltd
Incorporated in August 2015,
Bio Medica Laboratories Ltd
specialises in manufacturing
pharmaceutical parenteral
formulations, producing a
wide range of ethical drugs,
generic drugs, and over-the
-counter (OTC) medications[1]
- Market Cap ₹ 197 Cr.
- Current Price ₹ 157
- High / Low ₹ 164 / 102
- Stock P/E 16.9
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 44.5 %
- ROE 56.8 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 70.3%
Cons
- Debtor days have increased from 60.5 to 86.4 days.
- Working capital days have increased from 186 days to 329 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 16 | 15 | 38 | 38 | |
| 15 | 10 | 23 | 20 | |
| Operating Profit | 2 | 6 | 15 | 18 |
| OPM % | 10% | 37% | 40% | 48% |
| 0 | 0 | 0 | 0 | |
| Interest | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 1 | 1 | 1 |
| Profit before tax | 0 | 4 | 13 | 16 |
| Tax % | 27% | 32% | 25% | 26% |
| 0 | 2 | 10 | 12 | |
| EPS in Rs | 33.00 | 250.00 | 10.66 | 12.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 228% |
| TTM: | 19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| Last Year: | 57% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 9 | 9 |
| Reserves | 2 | 5 | 6 | 17 |
| 10 | 10 | 15 | 23 | |
| 6 | 4 | 9 | 8 | |
| Total Liabilities | 18 | 20 | 39 | 57 |
| 8 | 9 | 8 | 7 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 9 | 11 | 31 | 51 | |
| Total Assets | 18 | 20 | 39 | 57 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 2 | 2 | -4 | -6 | |
| -2 | -2 | 0 | -0 | |
| -2 | -0 | 3 | 6 | |
| Net Cash Flow | -2 | 0 | 0 | 0 |
| Free Cash Flow | 1 | 0 | -4 | -6 |
| CFO/OP | 147% | 31% | -16% | -9% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 92 | 56 | 39 | 86 |
| Inventory Days | 309 | 808 | 678 | 798 |
| Days Payable | 361 | 223 | 160 | 62 |
| Cash Conversion Cycle | 39 | 641 | 557 | 823 |
| Working Capital Days | -25 | 95 | 135 | 329 |
| ROCE % | 34% | 64% | 45% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Ampoule Capacity Utilization % |
|
||
| Ampoule Installed Capacity Nos. per Annum |
|||
| Ampoule Production Volume Nos. per Annum |
|||
| New Product Revenue Share % of Revenue from Operations |
|||
| Top 5 Customer Revenue Concentration % of Revenue from Operations |
|||
| Vial Capacity Utilization % |
|||
| Vial Installed Capacity Nos. per Annum |
|||
| Vial Production Volume Nos. per Annum |
|||
Extracted by Screener AI
Documents
Announcements
-
Appointment
- Ms. Khushi Gupta appointed Company Secretary, Compliance Officer and KMP on 14 August 2026.
-
Outcome of Board Meeting
- Board accepted Pratiksha Bhandari’s resignation and appointed Khushi Gupta as Company Secretary effective August 14, 2026.
-
Resignation of Director/KMP/SMP
- Bio Medica Laboratories Limited has informed about Resignation of Director/KMP/SMP
-
Resignation of Director/KMP/SMP
- Bio Medica Laboratories Limited has informed about Resignation of Director/KMP/SMP
-
Resignation of Director/KMP/SMP
- Bio Medica Laboratories Limited has informed about Resignation of Director/KMP/SMP
Business Profile:[1]
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, primarily generic injectable drugs.
The company manufactures liquid injections
and dry powder injections for both human
and veterinary use under a B2B/contract manufacturing model. Products are marketed
by client companies while Bio Medica acts
as the manufacturer.